Research Topics

Andrew M Tershakovec


Affiliation: Merck Research Laboratories
Country: USA


  1. request reprint
    Tershakovec A, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis. 2004;174:1-10 pubmed
  2. Ambegaonkar B, Tipping D, Polis A, Tomassini J, Tershakovec A. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 2014;237:829-37 pubmed publisher
    ..Adding ezetimibe to ongoing statin therapy appeared to be an effective option for patients who do not achieve lipid-lowering goals on statins alone. ..
  3. Rosen J, Ballantyne C, Hsueh W, Lin J, Shah A, Lowe R, et al. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015;14:103 pubmed publisher
    ..Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated. (Registered at NCT00409773). ..
  4. Davidson M, Tomassini J, Jensen E, Neff D, Polis A, Tershakovec A. Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis. 2016;246:121-9 pubmed publisher
    ..These trends are consistent with increased treatment and control of high LDL-C levels over recent years in clinical practice, and may influence the results of cIMT studies. ..